For FormBlends’s 2.5mg to units roundup, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last month a woman named Deb emailed me a photo of her insulin syringe next to her compounded tirzepatide vial. She’d been prescribed 2.5 mg. The vial read 10 mg/mL. She was pretty sure she needed to draw to the 25-unit line, but the numbers on the syringe barrel were small, she was nervous, and her telehealth provider’s instructions said “0.25 mL” while her syringe only showed unit markings. She wanted a second opinion before putting a needle in her stomach.
The short answer for Deb and everyone else in the same spot: at a 10 mg/mL concentration, 2.5 mg of tirzepatide equals 0.25 mL, which equals 25 units on a standard U-100 insulin syringe. That math is settled. The part that trips people up is the gap between how the prescription is written (milligrams), how the vial is labeled (milligrams per milliliter), and what the syringe actually measures (units). Three different measurement languages for one injection.
The Conversion Math (and Why It’s Simpler Than It Looks)
A U-100 insulin syringe is calibrated so that 100 units equals 1 mL. That’s the only fact you need to memorize. Everything else is division.
If your vial concentration is 10 mg/mL:
- 1 mg = 0.1 mL = 10 units
- 2.5 mg = 0.25 mL = 25 units
- 5 mg = 0.50 mL = 50 units
Here’s the full table for common tirzepatide doses at 10 mg/mL:
| Prescribed dose | Volume (at 10 mg/mL) | U-100 syringe units | |—|—|—| | 2.5 mg | 0.25 mL | 25 units | | 5 mg | 0.50 mL | 50 units | | 7.5 mg | 0.75 mL | 75 units | | 10 mg | 1.00 mL | 100 units | | 12.5 mg | 1.25 mL | 125 units (need a 1.5 mL syringe) | | 15 mg | 1.50 mL | 150 units (need a 1.5 mL syringe) |
The catch is that not every compounding pharmacy uses 10 mg/mL. Some ship vials at 5 mg/mL or 20 mg/mL. At 5 mg/mL, your 2.5 mg dose would be 0.50 mL (50 units). At 20 mg/mL, it would be 0.125 mL (12.5 units, which is nearly impossible to draw accurately on most syringes). If the concentration on your vial doesn’t match the conversion table your provider gave you, stop. Call before you inject. Dosing errors are reversible right up to the moment they aren’t.
See also: How Automation Technology Saves Time
What Tirzepatide Actually Does (Briefly)
Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two gut hormone pathways instead of one. Both pathways influence glucose regulation, appetite signaling, and the rate food leaves your stomach. Think of it like having two keys to the same building; semaglutide (Ozempic, Wegovy) uses one key, tirzepatide uses both.
The clinical results reflect that dual mechanism. In the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity who received tirzepatide over 72 weeks saw mean weight reductions of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. Those are population averages; individual responses ranged considerably, and the 2.5 mg starting dose is a titration step, not a therapeutic target.
Compounded tirzepatide uses the same active ingredient. The differences between compounded and branded (Mounjaro, Zepbound) are about manufacturing oversight, regulatory status, and supply chain, not molecular structure.
Drawing the Dose Without Messing It Up
I’ll be honest: most of the dosing anxiety I hear about isn’t about math. It’s about the physical act of drawing from a vial with a tiny syringe while your hands are slightly shaky because you haven’t done this before. Some practical notes:
Verify the vial label first. Read the concentration printed on the label. Match it against your prescribed dose calculation. Do this every time, even on your tenth vial.
Swab the vial septum with alcohol. Let it dry. Draw air into the syringe equal to the volume you plan to withdraw (25 units of air for a 25-unit draw), inject that air into the vial, then invert and draw.
Air bubbles happen. They’re annoying, not dangerous in a subcutaneous injection, but they do affect your dose accuracy. Tap the syringe barrel gently, push the bubble back into the vial, and redraw to the correct line.
Inject at 90 degrees into the abdomen (at least 2 inches from the navel) or outer thigh. Rotate sites. Injecting the same spot repeatedly causes lipohypertrophy, which is lumpy tissue that absorbs medication unpredictably.
Never reuse a syringe. Single-use means single-use. Reuse introduces contamination risk and dulls the needle, which makes the next injection hurt more.
Storage: Compounded tirzepatide vials go in the fridge (36 to 46°F). Pull the vial out 10 to 15 minutes before your injection so the solution warms to room temperature. Cold medication stings. Don’t speed this up with a microwave or hot water. Track your vial’s beyond-use date and number of draws. Discard on time even if there’s medication left.
Side Effects: What the Trials Actually Showed
GI symptoms dominate. The boring truth is that most people who start tirzepatide will feel nauseous at some point, usually in the first month and again at each dose escalation.
| Symptom | Trial frequency | Typical timing | What helps | |—|—|—|—| | Nausea | 30 to 45% | First 4 to 8 weeks; worse at dose increases | Smaller meals, lower fat intake, sipping water, antiemetics if persistent | | Diarrhea | 15 to 23% | Variable | Hydration, electrolytes, bland foods temporarily | | Constipation | 10 to 17% | Often after initial GI slowdown settles | 25 to 35 g fiber daily, hydration, magnesium if clinician approves | | Vomiting | 8 to 13% | First weeks and escalations | Hold dose, contact prescriber if it persists beyond 48 hours | | Reflux | 7 to 12% (frequently underreported) | Throughout therapy | No eating within 3 hours of bedtime, raise head of bed | | Fatigue | Variable | First weeks | Usually self-resolves; check ferritin, B12, TSH if it lingers |
Serious risks on the label include pancreatitis, gallbladder disease, severe hypoglycemia (particularly if combined with insulin or sulfonylureas), kidney injury from dehydration, and a boxed warning for medullary thyroid carcinoma based on rodent data.
Baseline labs worth getting before you start: comprehensive metabolic panel, HbA1c, fasting glucose, lipid panel, TSH, lipase (especially with any personal history of pancreatitis), and CBC. Repeat at 12 to 16 weeks, then roughly every 6 months once stable.
What It Costs in 2026
The price landscape is fragmented, which is part of why compounded tirzepatide exists as a market in the first place.
| Format | Typical monthly cash cost | Notes | |—|—|—| | Branded Zepbound (cash) | ~$1,059 retail; $499 via LillyDirect self-pay vial program | Self-pay vial pathway has eligibility criteria | | Branded Mounjaro (copay card) | $25 to $573 with eligibility | Off-label weight loss use generally not covered | | Compounded tirzepatide (503A) | $197 to $397 | Patient-specific prescription required; varies by dose tier | | Compounded tirzepatide (503B, office stock) | Varies by clinic markup | Clinic-administered or clinic-distributed |
HSA and FSA funds are typically eligible for prescription compounded medications with proper documentation. Keep itemized receipts.
A word on commitment terms: many telehealth providers offer quarterly or six-month plans at lower per-month pricing. Read the cancellation policy before you commit. Auto-renewal clauses in some of these agreements are, to put it charitably, not designed with the patient’s flexibility in mind.
When to Call Your Clinician (Organized by Urgency)
Immediately: Severe abdominal pain radiating to the back (pancreatitis concern), signs of serious dehydration, vision changes in diabetic patients, signs of allergic reaction.
Within a few days: Side effects substantially limiting daily function, vomiting beyond 48 hours, reflux that won’t respond to timing and positioning adjustments.
At your next routine visit: Dose pacing questions, weight loss plateau review, lab monitoring timing, long-term planning.
For the underlying clinical reference material on this conversion and related dosing context, FormBlends’s 2.5mg to units roundup maintains a structured resource that walks through the evidence hierarchy in more detail. It’s worth checking against whatever your telehealth provider includes in their onboarding packet.
Frequently Asked Questions
Is compounded tirzepatide right for me?
That’s a clinical decision, not a shopping decision. It depends on your BMI, metabolic markers, medication list, and medical history. A licensed clinician needs to evaluate and prescribe.
How quickly will I see results?
Most people notice appetite changes within 2 to 4 weeks and measurable weight loss by 8 to 12 weeks. SURMOUNT-1 data showed continued benefit through 72 weeks at therapeutic doses, but 2.5 mg is a starting/titration dose, not where most of the weight loss happens.
What side effects should I expect?
Nausea, constipation, diarrhea, and reduced appetite are the most common. The majority are manageable with slow titration and dietary adjustments. They tend to peak around dose increases and then fade.
How much does compounded tirzepatide cost?
Typically $197 to $397 per month cash pay through telehealth providers working with licensed compounding pharmacies. Branded options run significantly higher.
Can I stop taking it?
You can discontinue at any time under clinician guidance. Research consistently shows partial weight regain is common after stopping without structured lifestyle changes in place.
Is there a long-term safety profile?
Tirzepatide received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. Long-term data beyond 72 weeks continues to accumulate, but we don’t yet have the kind of decade-long safety picture that exists for older drug classes.
What if my vial concentration is different from 10 mg/mL?
Recalculate. At 5 mg/mL, a 2.5 mg dose would be 0.50 mL (50 units). At 20 mg/mL, it would be 0.125 mL (12.5 units). If you’re unsure, contact your prescriber or pharmacist before drawing.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B compounding pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
